Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...
The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body. However ...
Researchers have discovered a three-drug combination that enhances the generation of CAR-T cells, a type of cancer immunotherapy, and could improve CAR-T cell production for clinical treatments.
Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.
Treatment with the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) continued to demonstrate durable responses after a median follow-up of more than five years in patients with ...
Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the ...
This finding may have a significant impact on improving the production of CAR-T cells for clinical use. CAR-T cell immunotherapy involves harvesting immune-system T cells from a patient and ...